Effects of SNPs at newly identified lipids loci on blood lipid levels and risk of coronary heart disease in Chinese Han population: A case control study

Abstract

Associations between “lipid-related” candidate genes, blood lipid concentrations and coronary artery disease (CHD) risk are not clear. We aimed to investigate the effect of three newly identified lipids loci from genome-wide association studies on CHD and blood lipid levels in Chinese Han population. The genotypes of SNPs at three newly identified lipid loci and blood lipids concentrations were examined in 1360 CHD patients and 1360 age- and sex-frequency matched controls from an unrelated Chinese Han population. Allele T of rs16996148 occurred less frequently in CHD patients with the odds ratio (OR) being 0.64 (95% CI 0.50 to 0.81), after adjusting for conventional risk factors and was associated with a 33% decreased CHD risk (P<0.01) comparing with the major allele G. Individuals with GT genotype had the lowest CHD risk. No associations were found between the polymorphisms of other two loci with CHD risk and all three SNPs had no effect on lipid profile in this population. SNP rs16996148 on chromosome 19p13 is significantly associated with lower risk for CHD in Chinese Han population. However, it remains unresolved why these lipid-related loci had significantly less effects than the correspondingly expected effects on blood lipids levels in this population.

Keywords

coronary heart disease / blood lipids / lipid loci / single nucleotide polymorphism / Chinese Han population

References

[1] PiliaG., ChenW.M., ScuteriA., et al.. Heritability of cardiovascular and personality traits in 6148 Sardinians. PLoS Genet, 2006, 2(8): e132

[2] HellerD.A., de FaireU., PedersenN.L., et al.. Genetic and environmental influences on serum lipid levels in twins. N Engl J Med, 1993, 328(16): 1150-1156

[3] PollinT.I., HsuehW.C., SteinleN.I., et al.. A genome-wide scan of serum lipid levels in the Old Order Amish. Atherosclerosis, 2004, 173(1): 89-96

[4] KuulasmaaK., Tunstall-PedoeH., DobsonA., et al.. Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations. Lancet, 2000, 355(9205): 675-687

[5] KnoblauchH., BauerfeindA., ToliatM.R.. Haplotypes and SNPs in 13 lipid-relevant genes explain most of the genetic variance in high-density lipoprotein and low-density lipoprotein cholesterol. Human Molecular Genetics, 2004, 13(10): 993-1004

[6] LusisA.J., FogelmanA.M., FonarowG.C.. Genetic basis of atherosclerosis, part II: clinical implications. Circulation, 2004, 110: 2066-2071

[7] LusisA.J., MarR., PajukantaP.. Genetics of atherosclerosis. Annu Rev Genomics Hum Genet, 2004, 5: 189-218

[8] BreslowJ.L.. Genetics of lipoprotein abnormalities associated with coronary artery disease susceptibility. Annu Rev Genet, 2000, 34: 233-254

[9] ChasmanD.I., PareG., ZeeR.Y., et al.. Genetic loci associated with plasma concentration of low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein A1, and apolipoprotein B among 6382 white women in genome-wide analysis with replication. Circ Cardiovasc Genet, 2008, 1: 21-30

[10] CorboR.M., VilardoT., RuggeriM., et al.. Apolipoprotein E genotype and plasma levels in coronary artery disease. A case-control study in the Italian population. Clin Biochem, 1999, 32(3): 217-222

[11] BrazierL., TiretL., LucG., et al.. Sequence polymorphisms in the apolipoprotein(a) gene and their association with lipoprotein(a) levels and myocardial infarction. The ECTIM study. Atherosclerosis, 1999, 144: 323-333

[12] ScottL.J., MohlkeK.L., BonnycastleL.L., et al.. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science, 2007, 316(5829): 1341-1345

[13] ScuteriA., SannaS., ChenW.M., et al.. Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity related traits. PLoS Genet, 2007, 3(7): e115

[14] SaxenaR., VoightB.F., LyssenkoV., et al.. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science, 2007, 316: 1331-1336

[15] KathiresanS., MelanderO., GuiducciC., et al.. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet, 2008, 40(2): 189-197

[16] WillerC.J., SannalS., JacksonA.U., et al.. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet, 2008, 40(2): 161-169

[17] TaiE.S., SimX.L., OngT.H., et al.. Polymorphisms at newly identified lipid associated loci are associated with blood lipids and cardiovascular disease in an Asian Malay population. J Lipid Res, 2009, 50: 514-520

[18] Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health. . Organization task force on standardization of clinical nomenclature. Circulation, 1979, 59(3): 607-609

[19] ZhouL., ZhangX.M., HeM.A., et al.. Associations between single nucleotide polymorphisms on chromosome 9p21 and risk of coronary heart disease in Chinese Han population. Arterioscler Thromb Vasc Biol, 2008, 28(11): 2085-2089

[20] RauchU., FengK., ZhouX.H.. Neurocan: a brain chondroitin sulfate proteoglycan. Cell Mol Life Sci, 2001, 58(12–13): 1842-1856

[21] KeavneyB., PalmerA., ParishS., et al.. Lipid-related genes and myocardial infarction in 4685 cases and 3460 controls: discrepancies between genotype, blood lipid concentrations, and coronary disease risk. Int J Epidemiol, 2004, 33(5): 1002-1013

[22] VergesB.. Lipid modification in type 2 diabetes: the role of LDL and HDL. Fundam Clin Pharmacol, 2009, 23(6): 681-685

[23] TaskinenM.R.. Type 2 diabetes as a lipid disorder. Curr Mol Med, 2005, 5(3): 297-308

[24] MiyataM., SmithJ.D.. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and betaamyloid peptides. Nat Genet, 1996, 14(1): 55-61

[25] DavignonJ.. SchwartzC.J., BornG.V.R.. Apolipoprotein E polymorphism and atherosclerosis. New Horizons in Coronary Heart Disease, 1993, London, Current Science, 5.1-5.21

[26] CullenP., CignarellaA., BrennhausenB., et al.. Phenotype-dependent differences in apolipoprotein E metabolism and in cholesterol homeostasis in human monocyte-derived macrophages. J Clin Invest, 1998, 101(8): 1670-1677

[27] RiddellD.R., GrahamA., OwenJ.S.. Apolipoprotein E inhibits platelet aggregation through the L-arginine:nitric oxide pathway-Implications for vascular disease. J Biol Chem, 1997, 272(1): 89-95

[28] KellyM.E., ClayM.A., MistryM.J., et al.. Apolipoprotein E inhibition of proliferation of mitogen-activated T lymphocytes: production of interleukin-2 with reduced biological activity. Cell Immunol, 1994, 159(2): 124-139

[29] ZondervanK.T., CardonL.R.. The complex interplay among factors that influence allelic association. Nat Rev Genet, 2004, 5: 89-100